Collegium Pharmaceutical Inc (COLL) Expected to Post Quarterly Sales of $75.58 Million

Brokerages predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report sales of $75.58 million for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $71.04 million to $80.79 million. Collegium Pharmaceutical reported sales of $10.79 million in the same quarter last year, which indicates a positive year-over-year growth rate of 600.5%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, March 6th.

On average, analysts expect that Collegium Pharmaceutical will report full year sales of $282.14 million for the current year, with estimates ranging from $278.03 million to $287.77 million. For the next year, analysts forecast that the firm will post sales of $333.80 million, with estimates ranging from $325.78 million to $343.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The business had revenue of $70.20 million for the quarter, compared to analyst estimates of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. Collegium Pharmaceutical’s quarterly revenue was up 485.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.45) EPS.

A number of equities analysts have weighed in on the company. Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Friday. BidaskClub raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 27th. ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 13th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, November 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $31.71.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $16.60, for a total value of $415,000.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 13.87% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Highland Capital Management LP grew its position in shares of Collegium Pharmaceutical by 67.8% in the second quarter. Highland Capital Management LP now owns 508,822 shares of the specialty pharmaceutical company’s stock valued at $12,135,000 after purchasing an additional 205,600 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of Collegium Pharmaceutical by 23.6% in the second quarter. Commonwealth Equity Services LLC now owns 29,539 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 5,640 shares during the last quarter. Granahan Investment Management Inc. MA grew its position in shares of Collegium Pharmaceutical by 192.3% in the second quarter. Granahan Investment Management Inc. MA now owns 127,460 shares of the specialty pharmaceutical company’s stock valued at $3,040,000 after purchasing an additional 83,860 shares during the last quarter. Millennium Management LLC grew its position in shares of Collegium Pharmaceutical by 1,171.8% in the second quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after purchasing an additional 332,647 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Collegium Pharmaceutical by 203.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 155,374 shares of the specialty pharmaceutical company’s stock valued at $3,706,000 after purchasing an additional 104,255 shares during the last quarter.

Shares of NASDAQ COLL opened at $19.11 on Tuesday. The company has a market cap of $638.02 million, a price-to-earnings ratio of -7.74 and a beta of 0.28. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.75 and a current ratio of 0.78. Collegium Pharmaceutical has a twelve month low of $13.70 and a twelve month high of $29.90.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Article: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit